山茶油对阿尔兹海默症干预作用的代谢组学分析

摘要/Abstract

摘要： 摘要：目的：基于超高效液相色谱-四级杆飞行时间质谱（UPLC-Q/TOF-MS）技术，利用代谢组学方法探讨山茶油对Aβ25-35肽诱导的阿尔兹海默症（AD）小鼠的干预作用。方法：将小鼠随机分为正常对照组、模型组、阳性药组、山茶油处理组，留取尿液样本，沉淀蛋白后进行UPLC-Q/TOF-MS分析，获得小鼠尿液代谢轮廓图。将采集到的质谱原始数据导入SIMCA-P14.1软件中进行主成分分析和正交偏最小二乘判别分析确定潜在生物标志物，结合HMBD、MetaboAnalyst、KEGG等在线数据库对潜在生物标志物进行鉴定、通路富集分析和相关代谢网络的构建。结果：在PCA得分图中，山茶油组样本点远离模型组样本点区域，更接近正常组样本点区域，说明给予山茶油后，模型小鼠代谢轮廓向正常组靠近。共鉴定得到48个生物标志物（正源模式下33个，负源模式下15个），主要涉及的通路有牛磺酸和次牛磺酸代谢，精氨酸和脯氨酸代谢，半胱氨酸和蛋氨酸代谢，丙氨酸、天门冬氨酸和谷氨酸代谢等。结论：山茶油通过调节能量代谢、氨基酸代谢等通路干预AD小鼠体内代谢，改善AD小鼠症状，为山茶油干预阿尔兹海默症的进一步研究提供依据。

关键词: 代谢组学, 山茶油, 阿尔兹海默症, 通路, 液质联用

Abstract: Abstract: Purpose: Based on ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometer (UPLC-Q/TOF-MS) technique, the metabolomics method was used to investigate the intervention effect of camellia oil on Aβ25-35 peptide induced Alzheimer's disease (AD) mice. Methods: The mice were randomly divided into normal control group, model group, positive drug group, and camellia oil treatment group. Collecting urine samples and precipitate protein for UPLC-Q/TOF-MS analysis to obtain the urine metabolic profile of mice. The collected original mass spectrum data was imported into SIMCA-P14.1 software for principal component analysis and orthogonal partial least squares discriminant analysis to determine potential biomarkers. Combined with HMBD, MetaboAnalyst, KEGG and other online databases, potential biomarkers were identified, pathway enrichment analysis was performed and related metabolic network was constructed. Results: In PCA score chart, the sample points of camellia oil group were far away from the sample points of model group and closer to the sample points of normal group, indicating that the metabolic profile of model mice was closer to the normal group after administration of camellia oil. A total of 48 biomarkers were identified (33 in positive mode and 15 in negative mode), mainly involved in taurine and hypotaurine metabolism, arginine and proline metabolism, cysteine and methionine metabolism, alanine, aspartate and glutamate metabolism, etc. Conclusion: Camellia oil can regulate energy metabolism, amino acid metabolism and other pathways to intervene in the metabolism of AD mice and improve the symptoms of AD mice, which provides evidence for further research on the intervention of camellia oil in Alzheimer's disease.

Key words: Metabolomics, Camellia oil, Alzheimer's disease, Pathway, UPLC-MS

中图分类号:

R285.5

王瑞锋周宁陈龙刘通郭彭丽张冰贤张振凯曾梦楠郑晓珂冯卫生熊维政. 山茶油对阿尔兹海默症干预作用的代谢组学分析[J]. 食品科学.

wang ruifeng. Metabonomics analysis of the Intervention Effect of Camellia Oil on Alzheimer's Disease[J]. FOOD SCIENCE.

参考文献

[1]TOLEDO J B, ARNOLD M, KASTENMüLLER G, et al. Metabolic network failures in Alzheimer's disease: A biochemical road map[J]. Alzheimer's & dementia: the journal of the Alzheimer's Association, 2017, 13(9):965-984. DOI: 10.1016/j.jalz.2017.01.020. Epub 2017 Mar 22.
[2]BRIGGS R, KENNELLY S P, O'NEILL D. Drug treatments in Alzheimer's disease[J]. Clinical medicine (London, England), 2016, 16(3):247-53. DOI: 10.7861/clinmedicine.16-3-247.
[3]BRAAK H, BRAAK E. Frequency of stages of Alzheimer-related lesions in different age categories[J]. Neurobiology of aging,, 1997, 18(4):351-7. DOI: 10.1016/s0197-4580(97)00056-0.
[4]AMTUL Z, WESTAWAY D, CECHETTO D F, et al. Oleic acid ameliorates amyloidosis in cellular and mouse models of Alzheimer's disease[J]. Brain pathology (Zurich, Switzerland), 2011, 21(3):321-9. DOI: 10.1111/j.1750-3639.2010.00449.x.
[5]SCARMEAS N, STERN Y, TANG M, et al. Mediterranean diet and risk for Alzheimer's disease[J]. Annals of neurology, 2006, 59(6):912-21. DOI: 10.1002/ana.20854.
[6]PAN C, PRENTICE H, PRICE A L, et al. Beneficial effect of taurine on hypoxia-and glutamate-induced endoplasmic reticulum stress pathways in primary neuronal culture[J]. Amino Acids, 2012, 43(2):845-55. DOI: 10.1007/s00726-011-1141-6.
[7]MAO P, REDDY P H. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics[J]. Biochimica et biophysica acta, 2011, 1812(11):1359-70. DOI: 10.1016/j.bbadis.2011.08.005.
[8]WYSS M, KADDURAH-DAOUK R. Creatine and creatinine metabolism[J]. Physiological reviews, 2000, 80(3):1107-213. DOI: 10.1152/physrev.2000.80.3.1107.
[9]MAO P, REDDY P H. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics[J]. Biochimica et biophysica acta, 2011, 1812(11):1359-70. DOI: 10.1016/j.bbadis.2011.08.005.
[10]KENNEDY B P, BOTTIGLIERI T, ARNING E, et al. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function[J]. Journal of neural transmission (Vienna, Austria: 1996), 2004, 111(4):547-67. DOI: 10.1007/s00702-003-0096-5.
[11]PANZA F, CAPURSO C, D'INTRONO A, et al. S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in predementia syndromes and Alzheimer's disease[J]. Neurobiology of aging, 2008, 29(3):478-80. DOI: 10.1016/j.neurobiolaging.2006.10.013.
[12]WATKINS S M, ZHU X, ZEISEL S H. Phosphatidylethanolamine-N-methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice[J]. The Journal of nutrition, 2003, 133(11):3386-91. DOI: 10.1093/jn/133.11.3386.
[13]LEE V D S J, TEUNISSEN C E, POOL R et al. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies[J]. Alzheimer's & dementia: the journal of the Alzheimer's Association, 2018, 14(6):707-722. DOI: 10.1016/j.jalz.2017.11.012.
[14]TSAI G, COYLE J T. N-acetylaspartate in neuropsychiatric disorders[J]. Progress in neurobiology, 1995, 46(5):531-40. DOI: 10.1016/0301-0082(95)00014-m
[15]FOY C M, DALY E M, GLOVER A, et al. Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment[J]. Brain topography, 2011, 24(3-4):316-22. DOI: 10.1007/s10548-011-0170-5.
[16]SZUTOWICZ A, BIELARCZYK H, ZY?K M, et al. Early and Late Pathomechanisms in Alzheimer's Disease: From Zinc to Amyloid-β Neurotoxicity[J]. Neurochemical research, 2017, 42(3):891-904. DOI: 10.1007/s11064-016-2154-z.